Methods	Six-week randomised, double-blind multicentre study.
Participants	In- and outpatients fulfilling DSM-III criteria for major depressive episode, with a score of at least 17 on the HDRS-21. Age range: 20-86 years old. Exclusion criteria: suicide risk, other psychiatric disorder, alcohol abuse, use of MAOI in the previous 2 weeks, use of other antidepressants in the previous week, pregnancy, lactation, known allergy to trial medication
Interventions	Fluoxetine: 60 participants. Moclobemide: 62 participants. Fluoxetine dose range: 20-40 mg/day. Moclobemide dose range: 300-600 mg/day.
Outcomes	Primary outcome: Hamilton Rating Scale for Depression. Secondary outcome: CGI
Notes	Funding: unclear
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear